Literature DB >> 422700

Hyperglycemia per se (insulin and glucagon withdrawn) can inhibit hepatic glucose production in man.

J E Liljenquist, G L Mueller, A D Cherrington, J M Perry, D Rabinowitz.   

Abstract

We examined the effect of hyperglycemia per se on net splanchnic glucose balance. In 2 groups of normal postabsorptive men who had undergone hepatic vein catheterization, somatostatin was administered to block endogenous insulin and glucagon secretion. Exogenous glucose was infused in both groups to maintain euglycemia for 2 h in one group (n = 7) and to induce hyperglycemia of 220-240 mg/dl after 30 minutes of euglycemia in the second group (n = 4). In both groups the induction of insulinopenia and glucagonopenia with euglycemia maintained resulted in an initial 75% fall in net splanchnic glucose production (NSGP). In the group in which euglycemia was maintained NSGP returned to basal rates (157 +/- 31 mg/min) within 2 h. However, in the group in which hyperglycemia was induced, NSGP did not return to basal rates but remained suppressed (28 +/- 4 mg/min) for the duration of the study. These data in normal man indicate that hyperglycemia per se with insulin and glucagon acutely withdrawn can suppress splanchnic glucose production but does not induce net splanchnic glucose storage.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 422700     DOI: 10.1210/jcem-48-1-171

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Intraportal glucose delivery enhances the effects of hepatic glucose load on net hepatic glucose uptake in vivo.

Authors:  S R Myers; D W Biggers; D W Neal; A D Cherrington
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Inhibiting gluconeogenesis prevents fatty acid-induced increases in endogenous glucose production.

Authors:  Sylvia Kehlenbrink; Julia Tonelli; Sudha Koppaka; Visvanathan Chandramouli; Meredith Hawkins; Preeti Kishore
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-05-05       Impact factor: 4.310

3.  Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration.

Authors:  S R Myers; O P McGuinness; D W Neal; A D Cherrington
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

4.  Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans.

Authors:  K F Petersen; D Laurent; D L Rothman; G W Cline; G I Shulman
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

5.  Separation of physiological factors influencing glucose-insulin kinetics in diabetic patients.

Authors:  B G Min; E J Woo; H K Lee; H K Min
Journal:  Ann Biomed Eng       Date:  1985       Impact factor: 3.934

6.  Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion.

Authors:  J C Pickup; G C Viberti; R W Bilous; H Keen; K G Alberti; P D Home; C Binder
Journal:  Diabetologia       Date:  1982-03       Impact factor: 10.122

7.  Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

Authors:  D A D'Alessio; S E Kahn; C R Leusner; J W Ensinck
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  Differential effects of insulin on splanchnic and peripheral glucose disposal after an intravenous glucose load in man.

Authors:  L Saccà; M Cicala; B Trimarco; B Ungaro; C Vigorito
Journal:  J Clin Invest       Date:  1982-07       Impact factor: 14.808

9.  Differential roles of splanchnic and peripheral tissues in the pathogenesis of impaired glucose tolerance.

Authors:  L Saccà; G Orofino; A Petrone; C Vigorito
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

10.  Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man.

Authors:  W Waldhäusl; P Bratusch-Marrain; S Gasic; A Korn; P Nowotny
Journal:  Diabetologia       Date:  1979-10       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.